

## Table of Contents

**Preface** *xix*

### **Volume I**

**1 Inflammation through the Ages: A Historical Perspective** *1*  
*Jean-Marc Cavaillon*

### **Part One Inducers and Sensors of Inflammation** *17*

**2 Pathogen-associated Molecular Patterns** *19*  
*Jean-Marc Cavaillon*

**3 Damage-associated Molecular Patterns** *57*  
*Jean-Marc Cavaillon*

**4 Bacterial Toxins** *81*  
*Marina de Bernard and Cesare Montecucco*

**5 Venoms** *99*  
*Catarina Teixeira, Vanessa Moreira, and José María Gutiérrez*

**6 Hypoxia as an Inducer of Inflammation** *129*  
*Ariel Brandwein and Clifford S. Deutschman*

**7 Vaccine Adjuvants** *143*  
*Dennis M. Klinman and Hidekazu Shirota*

**8 Pattern Recognition Receptors** *175*  
*Lauren Whitehead and Gordon D. Brown*

**Part Two Inflammatory Cells 217**

- 9 Monocytes and Macrophages 219**  
*Irina N. Shalova, Shilpi Saha, and Subhra K. Biswas*
- 10 Neutrophils 253**  
*Salvatore Cuzzocrea*
- 11 Mast Cells: Master Drivers of Immune Responses against Pathogens 273**  
*W.X. Gladys Ang and Soman N. Abraham*
- 12 Dendritic Cells in Inflammatory Disease 289**  
*Bart N. Lambrecht, Martin Guillems, and Hamida Hammad*
- 13 Roles for NK Cells and ILC1 in Inflammation and Infection 315**  
*Christian A.J. Vosshenrich and James P. Di Santo*
- 14 Group 2 and 3 Innate Lymphoid Cells: New Actors in Immunity and Inflammation 341**  
*Nicolas Serafini and James P. Di Santo*
- 15 Th9 Cells: From the Bench to the Bedside and Back Again 365**  
*Benjamin J. Ulrich, Matthew M. Hufford, and Mark H. Kaplan*
- 16 Th17 Cells 395**  
*Mélissa Noack and Pierre Miossec*
- 17 Platelets 419**  
*Jack Levin*
- 18 Epithelial Cells 437**  
*Jill M. Hoffman and Charalabos Pothoulakis*
- 19 Inflammation: The Role of Endothelial Cells 457**  
*J. Steven Alexander, D. Neil Granger, and Norman R. Harris*

**Volume II**

**Part Three Inflammatory Mediators 477**

- 20 IL-1 Superfamily and Inflammasome 479**  
*Charles A. Dinarello*
- 21 TNF Superfamily 529**  
*Salvatore Cuzzocrea*

- 22    **Interleukin-17 A-E**    549  
       *Giovanni Monteleone, Irene Marafini, and Edoardo Troncone*
- 23    **IL-6 Superfamily**    573  
       *Toshio Tanaka, Masashi Narazaki, and Tadamistu Kishimoto*
- 24    **Type I and II Cytokine Superfamilies in Inflammatory Responses**    587  
       *William F. Carson IV and Steven L. Kunkel*
- 25    **Chemokines and Chemotaxis**    619  
       *Osamu Yoshie and Kouji Matsushima*
- 26    **Lipid Mediators in Inflammation**    651  
       *Shuh Narumiya, Takehiko Yokomizo, and Junken Aoki*
- 27    **Free Radicals in Inflammation**    695  
       *Andrew Cumpstey and Martin Feelisch*
- 28    **Proteases**    727  
       *Celine Deraison, Chrystelle Bonnard, and Nathalie Vergnolle*
- 29    **Psychiatric Disorders and Inflammation**    767  
       *Robert Dantzer*
- 30    **Complement System**    785  
       *Peter A. Ward and Claudia Kemper*
- 31    **Heat Shock Proteins**    813  
       *Willem van Eden, Femke Broere, and Ruurd van der Zee*

### Volume III

#### Part Four    Inflammation and Host Response    831

- 32    **Inflammation and Coagulation**    833  
       *Marcel Levi*
- 33    **Fever: Mediators and Mechanisms**    861  
       *Joachim Roth*
- 34    **Pain**    891  
       *Christoph Stein*
- 35    **Inflammation, Hormones, and Metabolism**    915  
       *Muska Khpal and Mervyn Singer*

- 36      Microenvironmental Regulation of Innate Immune  
Cell Function    947**  
*Emily R. Watts, Eilise Ryan, Sarah R. Walmsley, and Moira K.B. Whyte*
- 37      Epigenetics of Inflammation    971**  
*Vidula Vachharajani and Charles E. McCall*
- Part Five    Inflammation and Diseases    993**
- 38      Allergy and Inflammation    995**  
*Milena Sokołowska, Anna Głobińska, and Cezmi A. Akdis*
- 39      Sepsis    1031**  
*Manu Shankar-Hari and Mervyn Singer*
- 40      Autoimmunity and Inflammation    1053**  
*Shrikant Ramesh Mulay, Onkar P. Kulkarni, Khader Rupanagudi,  
and Hans-Joachim Anders*
- 41      Psoriasis and Other Skin Inflammatory Diseases    1091**  
*Jaehwan Kim and James G. Krueger*
- 42      Rheumatoid Arthritis and Other Inflammatory Articular  
Diseases    1105**  
*Rogier M. Thurlings, Sander W. Tas, and Paul Peter Tak*
- 43      Missing Heritability of Crohn's Disease and Implications for  
Therapeutic Targeting and Improved Care    1141**  
*Matthias Chamaillard*
- 44      Inflammation and Transplantation    1147**  
*William M. Baldwin, III and Robert L. Fairchild*
- 45      Inflammatory Mechanisms in Chronic Obstructive Pulmonary  
Disease    1173**  
*Peter J. Barnes*
- 46      Obesity: A Complex Disease with Immune Components    1199**  
*Yuejun Liu and Karine Clément*
- 47      Inflammation and Type 2 Diabetes    1225**  
*Marleen M.J. van Greevenbroek, Casper G. Schalkwijk,  
and Coen D.A. Stehouwer*

- 48 Inflammation-Mediated Neurodegeneration: Models, Mechanisms, and Therapeutic Interventions for Neurodegenerative Diseases 1255**  
*Hui-Ming Gao, Yun Gao, Dezhen Tu, Yue Liu, Hui Zhou, and Jau-Shyong Hong*
- 49 Inflammation in Atherosclerosis 1279**  
*Mario A.R. Lauterbach, Larisa I. Labzin, and Eicke Latz*
- 50 Acute Kidney Injury 1301**  
*Johan Mårtensson and Rinaldo Bellomo*
- 51 Ischemia-Reperfusion Syndrome 1313**  
*Christophe Adrie, Sally A. Shin, and Mehran Monchi*
- 52 Single-Nucleotide Polymorphisms and Inflammation 1329**  
*Evangelos J. Giamarellos-Bourboulis*

#### Volume IV

#### Part Six Resolution of Inflammation and Tissue Repair 1347

- 53 Pentraxins in the Orchestration of Defense and Tissue Repair during the Acute Phase Response 1349**  
*Alberto Mantovani, Cecilia Garlanda, and Barbara Bottazzi*
- 53.1 The General Scenario 1349
- 53.2 Genes and Proteins 1351
- 53.3 Microbial Recognition 1353
- 53.4 Complement and FcγR 1354
- 53.5 Tissue Repair 1355
- 53.6 Concluding Remarks 1356
- References 1356
- 54 Anti-Inflammatory Cytokines, Soluble Receptors, and Natural Antagonists 1363**  
*Willem Joost Wiersinga and Tom van der Poll*
- 54.1 Introduction 1363
- 54.2 Anti-Inflammatory Cytokines and Soluble Receptors 1363
- 54.2.1 Regulation of the Activity of IL-1 Family Cytokines 1363
- 54.2.2 IL-2 1366
- 54.2.3 IL-6 1366
- 54.2.4 IL-10 1366
- 54.2.5 IL-27 and IL-35 1367
- 54.2.6 Transforming Growth Factor-β 1368

54.2.7	Soluble Cytokine Receptors	1369
54.3	Negative Regulation of Toll-Like Receptor-Mediated Immune Responses	1369
54.3.1	Soluble Decoy Toll-Like Receptors	1371
54.3.2	Soluble ST2	1371
54.3.3	Soluble TREM-2	1372
54.4	Additional Anti-Inflammatory Mechanisms	1372
54.5	Concluding Remarks	1373
	References	1373
<b>55</b>	<b>Regulatory T Cells</b>	<b>1377</b>
	<i>Luciana Berod, Katharina Lahl, Matthias Lochner, Christian T. Mayer, and Tim Sparwasser</i>	
55.1	Introduction	1377
55.2	T <sub>REG</sub> Subpopulations	1379
55.2.1	Thymus-Derived versus Peripherally Derived T <sub>REGS</sub>	1379
55.2.2	Molecular Mechanisms Underlying T <sub>REG</sub> Differentiation	1380
55.2.3	Effector T <sub>REGS</sub> (eT <sub>REGS</sub> )	1386
55.2.4	Nonlymphoid Tissue-Resident T <sub>REG</sub> Cells	1389
55.2.4.1	Adipose Tissue T <sub>REGS</sub>	1389
55.2.4.2	Intestinal T <sub>REGS</sub>	1390
55.3	Control of Immunity to Self-Tissues by Foxp3 <sup>+</sup> T <sub>REGS</sub>	1391
55.3.1	Autoimmunity	1391
55.3.2	Cancer	1393
55.4	T <sub>REGS</sub> in the Context of Infections	1394
55.4.1	Viral Infections	1395
55.4.2	Bacterial Infections	1396
55.4.3	Fungal Infections	1397
55.4.4	Parasitic Infections	1398
55.5	Clinical Perspectives	1399
	Acknowledgments	1400
	References	1400
<b>56</b>	<b>Leukocyte Reprogramming</b>	<b>1423</b>
	<i>Jean-Marc Cavaillon</i>	
56.1	Introduction	1423
56.2	Endotoxin Tolerance	1423
56.3	Cross-tolerance	1425
56.4	From Endotoxin Tolerance to PRRs Ligands Tolerance	1426
56.5	Does Endotoxin Tolerance Affect Anti-Infectious Immunity?	1427
56.6	Clinical Relevance	1427
56.7	From Tolerance to Reprogramming	1428
56.8	Reversal	1429
56.9	Mechanisms	1429
56.9.1	Anti-Inflammatory Cytokines	1429

56.9.2	Glucocorticoids	1430
56.9.3	Regulatory Signaling Downstream TLRs	1430
56.9.4	Epigenetics	1431
56.9.5	miRNA	1431
56.10	Macrophage Plasticity	1432
	References	1433
<b>57</b>	<b>Roles of Specialized Proresolving Lipid Mediators in Inflammation Resolution and Tissue Repair</b>	<b>1447</b>
	<i>Matthew Spite and Charles N. Serhan</i>	
57.1	Resolution of Acute Inflammation: Identification of Specialized Proresolving Mediators	1447
57.2	Lipid Mediator Class Switching During Inflammation and Its Resolution	1449
57.3	Lipoxins	1449
57.4	E-series Resolvins	1451
57.5	D-series Resolvins	1454
57.6	Novel Statin-Induced 13-Series Resolvins	1457
57.7	Role of Novel Sulfido Lipid Mediator Conjugates in Tissue Regeneration	1457
57.8	Summary	1458
	Acknowledgments	1458
	References	1458
<b>58</b>	<b>Glucocorticoids</b>	<b>1467</b>
	<i>Heming Nicholas and Annane Djillali</i>	
58.1	Introduction	1467
58.1.1	Historical Introduction	1467
58.1.2	Corticosteroid Biosynthesis	1468
58.1.3	Hypothalamic–Pituitary–Adrenal Axis	1469
58.2	Pharmacokinetics	1470
58.3	Mechanisms of Action	1471
58.3.1	Genomic Effect of Glucocorticoids	1471
58.3.2	Nongenomic Effect of Glucocorticoids	1473
58.4	Pharmacological Effects	1474
58.4.1	Immunomodulation	1474
58.4.1.1	Innate Immunity	1474
58.4.1.2	Adaptive Immunity	1474
58.4.2	Other Effects	1475
58.5	Therapeutic Use of Glucocorticoids	1475
58.5.1	General Principles	1475
58.5.2	Allergy and Asthma	1476
58.5.3	Rheumatic Disorders	1476
58.5.4	Renal Diseases	1476
58.5.5	Preventing Graft Rejection	1477
58.5.6	Infectious Diseases	1477
58.5.7	Adrenal Insufficiency	1477

58.5.8	Miscellaneous	1477
References		1478

<b>59</b>	<b>The Neuroimmune Communicatome in Inflammation</b>	<b>1485</b>
	<i>Peder S. Olofsson, Christine N. Metz, and Valentin A. Pavlov</i>	
59.1	Introduction	1485
59.2	What is Inflammation?	1485
59.3	Neuroimmune Dialogue in Inflammation and the Concept of the Neuroimmune Communicatome	1486
59.3.1	Major Components of the Neuroimmune Communicatome	1488
59.3.2	Reflex Principles: The Inflammatory Reflex and Beyond	1490
59.4	Points of Interaction in the Neuroimmune Communicatome	1492
59.4.1	How the Nervous System Is Affected in Peripheral Inflammation	1492
59.4.1.1	Neurogenic Inflammation	1493
59.4.1.2	Neural Sensing of Inflammation	1493
59.4.1.3	Brain Function in Peripheral Inflammation	1494
59.4.2	How Immune Functions and Inflammation Are Regulated by the Nervous System	1496
59.4.2.1	Neural Regulation of Immune Cell Trafficking and Infiltration	1496
59.4.2.2	Neurotransmitters in Neuronal Circuits Controlling Inflammation	1497
59.4.2.3	Neural Regulation of Inflammation Resolution	1498
59.4.2.4	Immune Cells and Cells with Immune Function in the Periphery Implement the Neuronal Repertoire	1499
59.4.2.5	The Brain as an Active Player in the Regulation of Peripheral Inflammation: Focusing on Cholinergic Mechanisms	1501
59.5	Translational Exploration Based on the Neuroimmune Communicatome	1502
59.5.1	Pharmacological Anti-Inflammatory Approaches Based on the Inflammatory Reflex	1503
59.5.2	Bioelectronic Medicine	1503
59.6	Conclusions	1504
Acknowledgments		1505
Abbreviations		1505
References		1506

<b>60</b>	<b>The Inflammatory Response in Tissue Repair</b>	<b>1517</b>
	<i>Nikolaos G. Frangogiannis</i>	
60.1	Introduction	1517
60.2	Initiation of the Inflammatory Response Following Injury: The Alarmins	1517
60.3	The Complement Cascade	1519
60.4	Induction and Release of Proinflammatory Cytokines	1519



60.5	Chemokines Regulate Leukocyte Recruitment	1520
60.6	Leukocyte Recruitment in Sites of Injury	1521
60.7	The Role of Neutrophils in Injured Tissues	1522
60.8	Repression and Resolution of Inflammation: The Stop Signals	1522
60.8.1	Negative Regulation of Cytokine Signaling	1523
60.8.2	Anti-Inflammatory Cytokines	1523
60.8.3	Lipid Mediators in Resolution of Postinfarction Inflammation	1523
60.8.4	Inhibition of the Leukocyte Adhesion Cascade	1523
60.9	The Cellular Effectors of Resolution of Inflammation	1524
60.10	The Extracellular Matrix	1525
60.11	Tissue-Specific Events Leading to Regeneration	1525
60.12	Fibroblast Activation and Formation of a Scar	1526
60.13	Concluding Remarks	1528
	Sources of Funding	1528
	References	1528

## **Part Seven Detection and Treatments 1539**

<b>61</b>	<b>Biomarkers in Inflammation</b>	<b>1541</b>
	<i>Andreas Kortgen and Michael Bauer</i>	
61.1	Acute-Phase Reactants	1542
61.2	Pentraxins	1542
61.3	C-Reactive Protein (CRP)	1543
61.4	Pentraxin 3	1543
61.5	Procalcitonin	1544
61.6	Interleukin 6	1546
61.7	Lipopolysaccharide-Binding Protein (LBP)	1546
61.8	Presepsin (Soluble CD14 Subtype)	1547
61.9	Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1)	1548
61.10	Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR)	1549
61.11	Adrenomedullin	1549
61.12	CD64	1550
61.13	Panels of Combined of Biomarkers	1551
61.14	Multiplexed Molecular Markers Derived from “Omics” Technologies	1552
	References	1553
<b>62</b>	<b>In Vivo Imaging of Inflammation</b>	<b>1567</b>
	<i>Anne Roivainen and Antti Saraste</i>	
62.1	Introduction	1567
62.2	Methods for Inflammation Imaging	1568
62.2.1	Nuclear Imaging	1568
62.2.1.1	Positron Emission Tomography	1568

	62.2.1.2 Single-Photon Emission Computed Tomography	1572
	62.2.2 Computed Tomography	1572
	62.2.3 Magnetic Resonance Imaging	1573
	62.2.4 Ultrasound	1573
	62.2.5 Multimodal and Hybrid Imaging	1573
62.3	Clinical Inflammation Imaging	1574
	62.3.1 Suspected Systemic and Local Infections	1574
	62.3.2 Vasculitis	1575
	62.3.3 Sarcoidosis	1576
	62.3.4 Other Applications	1577
62.4	Emerging Protocols for Inflammation Imaging	1578
	References	1581
<b>63</b>	<b>Novel Targets for Drug Development</b>	<b>1583</b>
	<i>Alan S. Cross and Steven M. Opal</i>	
63.1	Introduction	1583
	63.1.1 Targeting the Pathogen PAMPs, Their Toxins and Virulence Factors	1584
	63.1.1.1 Opsonic Antibodies and Antivirulence Factor Therapies	1584
	63.1.1.2 Bacteriophage Therapy	1584
	63.1.1.3 Hemoperfusion Systems to Clear Pathogens and PAMPs	1584
	63.1.1.4 Engineered Liposomes to Clear Exotoxins	1586
	63.1.1.5 Antivirulence Factor Therapy or Quorum-Sensing Inhibitors	1586
	63.1.1.6 Tyrosine Kinase Inhibitors and Other Novel Antibacterial Agents	1586
	63.1.1.7 New Antibiotic Combinations	1586
	63.1.1.8 Defensins and Antibacterial Peptides	1587
	63.1.2 Targeting DAMPs and the Host Response to DAMPs and PAMPs	1587
	63.1.2.1 Statins	1588
	63.1.2.2 Histone Inhibitors	1590
	63.1.2.3 Extracellular and Intracellular Signaling Inhibitors	1590
	63.1.2.4 Receptor for Advanced Glycation End Products (RAGE) Inhibitors	1591
	63.1.2.5 Recombinant Gelsolin and TREM-1	1591
	63.1.2.6 High Mobility Group Box 1	1592
	63.1.2.7 Proresolving Agents	1592
	63.1.3 Epithelial Membrane Barriers and Microbiome as a Target for Sepsis	1592
	63.1.4 Targeting the Vascular Endothelium in Acute Inflammatory States	1594

63.1.5	Immunomodulators and Other Promising new Therapeutic Targets	1595
63.1.5.1	Immune Reconstitution as a Molecular Target	1595
63.1.5.2	Immune Reconstitution Strategies as a Therapy for Sepsis	1596
63.1.5.3	Mesenchymal Stem Cells as a Therapy for Sepsis	1596
63.1.5.4	Mitochondrial Sparing agents and Immunometabolism as a Target for Sepsis	1596
63.1.5.5	CD28 Costimulatory Signal Peptide Inhibitors as a Novel Therapy for Sepsis	1598
63.1.5.6	The Return of Interleukin-1 Receptor Antagonist (IL-1ra) in Systemic Inflammation	1598
63.2	Conclusion	1598
	References	1599
<b>64</b>	<b>Inflammation and Microbiota and Gut Reconditioning</b>	<b>1609</b>
	<i>Stig Bengmark</i>	
64.1	A Dramatic Increase in Incidence of Chronic Diseases	1609
64.2	The Epidemic Forecasted to Continue – Also in the Western World	1610
64.3	Developing Countries Soon to Take Over the “Yellow Jersey”	1610
64.4	Hypertension Associated with Dysbiosis	1611
64.5	Inflammation – A Mother of Disease	1611
64.6	The Gut Harbors the Majority of the Immune System	1612
64.7	Strong Association Between Composition of Microbiota and Chronic Diseases	1612
64.8	Paleolithic Forefathers Had a Much Different, Much More Diverse and Richer Microbiota	1613
64.9	Different Microbiota in Infants in Hunting and Gathering Communities	1614
64.10	The Most Robust Microbiota Ever Seen	1614
64.11	Rural Lifestyle Prevents Western Diseases	1615
64.12	Endotoxin (LPS) – A Major Inducer of Inflammation and Disease	1616
64.13	Meals Rich in Long-Chain Fatty Acids Induce Endotoxemia	1616
64.14	Humans Are Especially Sensitive to Endotoxin	1617
64.15	Fresh Fruits and Vegetables Contain Minimal Levels of Stimulants of Toll-Like Receptors (TLRs)	1617
64.16	Several Proteotoxins Stimulate Also Toll-Like Receptors (TLR) and Induce/Enhance Inflammation	1617
64.17	Gluten-Sensitivity a Common and Newly Detected Inflammation-Inducing Disorder	1618
64.18	Gluten-Free Foods Have Led to a New and Successful Industry	1619
64.19	Glutenoids Show Endotoxin-Mimicking Abilities	1619
64.20	Similar Effects Observed on Gluten Restriction in Individuals with ADHD	1620

64.21	Gluten Sensitivity Associated with Severe Dysbiosis, Leaky Gut and Increased General Inflammation	1620
64.22	Proteotoxin-Induced Low Threshold for Immune Response	1621
64.23	Heat- and Storage-Induced Inflammation-Inducing Proteins	1621
64.24	Numerous Proinflammatory Mediators Involved	1622
64.25	Short-Chain Fatty Acids – A Magic Bullet?	1622
64.26	Consumption of Plant Fibers Crucial to Eubiosis and Good Health	1623
64.27	Prebiotic Fibers Generally Resistant to Digestion in the Small Intestine	1623
64.28	It Is the Luminal Levels of SCFAs, Which Make the Difference	1624
64.29	Not only SCFAs but MCFAs Have Strong Ability to improve Immunity and Prevent Disease	1624
64.30	Stress Increases Microbial Growth and Virulence	1625
64.31	Early-Life Conditions Influence Long-Term Health	1625
64.32	Psychological Stress Impairs Microbiota	1626
64.33	Physical Exercise Increases Microbiota Numbers and Diversity	1626
64.34	Exercise Has Positive and Negative Effects on Immunity Depending on Its Intensity	1627
64.35	Postprandial Inflammation a “Deadly” Threat to Long-Term Health	1627
64.36	Abdominal/Visceral Obesity Enhances Postprandial Inflammation	1628
64.37	Postprandial Inflammation Are Induced by Long-Chain but Not Medium-Chain Fatty Acids	1629
64.38	Reduced Intake of LCFAs and Increased Intake of MCFAs Good for Microbiota and Health	1630
64.39	Gut Reconditioning – An Important Tool to Maintain Optimal Health	1631
	64.39.1 Allergies	1631
	64.39.2 ADHD	1632
	64.39.3 Autoimmune Diseases	1632
64.40	Cancer	1633
64.41	Childhood Diarrhea	1633
	64.41.1 Critical Illness	1633
	64.41.2 HIV – Virologic Suppression	1634
	64.41.3 Metabolic Syndrome and Diabetes	1634
	64.41.4 Gastrointestinal Disorders	1634
	64.41.5 Liver Disease	1635
	64.41.6 Renal Disease	1636
	64.41.7 Respiratory	1637
	64.41.8 Toxic Exposure	1637
64.42	Fecal Microbiota Transplantation (FMT) – A Giant Step Forward	1638
64.43	Synbiotics – A Less Invasive Alternative	1638
64.44	Less Suffering for the Patients – Great Savings for Society	1640

64.45	Ecobiological Functions – Same but Different Response Compared to So-Called Biological Drugs	1641
	References	1642
<b>65</b>	<b>Natural Products as Source of Anti-Inflammatory Drugs</b>	<b>1661</b>
	<i>Shivaprasad H. Venkatesha, Bodhraj Acharya, and Kamal D. Moudgil</i>	
65.1	Introduction	1661
65.2	Cellular, Molecular, and Biochemical Pathways of Inflammation	1664
65.2.1	Inflammation Triggered by Innate Immune Responses	1664
65.2.2	Inflammation Triggered by Adaptive Immune Responses	1666
65.2.3	Cell Signaling Pathways involved in inflammation	1667
65.2.3.1	The Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF- $\kappa$ B) Pathway	1667
65.2.3.2	Mitogen-Activated Protein Kinase (MAPK) Pathway	1667
65.2.3.3	The Janus Kinase (JAK)-Signal Transducer and Activator of Transcription (STAT) Pathway	1671
65.2.3.4	The Phosphatidylinositol-3-Kinase (PI3K)/Akt/Mammalian Target of Rapamycin (mTOR) Pathway	1672
65.2.3.5	The Arachidonic Acid Pathway	1672
65.2.3.6	Nitric Oxide (NO), Inducible Nitric Oxide Synthase (iNOS), and Inflammation	1672
65.2.3.7	Other Pathways Associated with Inflammation	1673
65.3	Natural Products from Diverse Sources Possess Anti-Inflammatory Activity	1673
65.4	Technological Advancements in the Production, Characterization, and Delivery of Natural Products	1675
65.4.1	Semisynthesis, Combinatorial Biosynthesis, and Metabolic Engineering	1675
65.4.2	High-Throughput Screening (HTS) and Virtual Screening	1676
65.4.3	Microarrays	1676
65.4.4	Systems Pharmacology	1676
65.4.5	Use of Nanotechnology to Deliver Natural Products for Therapeutic Purposes	1677
65.5	Concluding Remarks	1677
	References	1678
	<b>Index</b>	<b>1691</b>